Smith & Nephew PLC Sponsored ADR Stock

$31.48

0.80% day before yesterday

NYSE, Sep 06, 10:10 pm CET

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Smith & Nephew PLC Sponsored ADR Stock price

$31.48

-17.09 35.19% 5Y

NYSE, Closing price Fri, Sep 06 2024

+0.25 0.80%

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$13.72b
Enterprise Value	$16.81b
P/E (TTM) P/E ratio	45.10
EV/FCF (TTM) EV/FCF	56.12
EV/Sales (TTM) EV/Sales	2.99
P/S ratio (TTM) P/S ratio	2.44
P/B ratio (TTM) P/B ratio	2.64
Dividend yield	2.38%
Last dividend (FY24)	$0.75
Revenue growth (TTM) Revenue growth	2.60%
Revenue (TTM) Revenue	$5.62b
EBIT (operating result TTM) EBIT	$828.44m
Free Cash Flow (TTM) Free Cash Flow	$299.56m
EPS (TTM) EPS	$0.70
P/E forward	28.41
P/S forward	2.36
EV/Sales forward	2.89
Short interest	0.16%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Smith & Nephew PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

19 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

12x Buy

63%

7x Hold

37%

More details on Analyst Estimates Including Price Targets

19 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

Buy

63%

Hold

37%

Analyst Estimates with Stock Price Targets

Financial data from Smith & Nephew PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	5,620 5,620	3% 3% 100%
- Direct Costs	1,740 1,740	6% 6% 31%
Gross Profit	3,880 3,880	1% 1% 69%
- Selling and Administrative Expenses	2,087 2,087	4% 4% 37%
- Research and Development Expense	309 309	11% 11% 5%
EBITDA	1,484 1,484	13% 13% 26%
- Depreciation and Amortization	656 656	6% 6% 12%
EBIT (Operating Income) EBIT	828 828	19% 19% 15%
Net Profit	304 304	38% 38% 5%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Smith & Nephew PLC Sponsored ADR Stock News

Positive

Seeking Alpha

●

17 days ago

Smith & Nephew Delivering On Its Turnaround Promise

The Street has taken notice of Smith & Nephew's turnaround progress, with better than expected revenue and margin results driving share price outperformance. While the ortho business has continued to grow, SNN has continued to lose share in major joints and this is the biggest item on management's to-do list now. Management has identified additional savings opportunities that will help boost ma...

Neutral

Seeking Alpha

●

about one month ago

Smith & Nephew plc (SNN) Q2 2024 Earnings Call Transcript

Smith & Nephew plc (NYSE:SNN ) Q2 2024 Results Conference Call August 1, 2024 2:00 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants David Adlington - JD Morgan Sebastien Jantet - Panmure Liberum Richard Felton - Goldman Sachs Graham Doyle - UBS Samuel Joh - Berenberg Caitlin Cronin - Canaccord Genuity Julien Dorm...

Positive

Proactive Investors

●

about one month ago

Smith & Nephew jumps on progress with turnaround of hip and knee arm

Shares in Smith & Nephew PLC (LSE:SN) sprang 7.7% higher as the replacement hip and knee specialist reported some encouraging elements in its interim results. Overall, the numbers for the first half ended 29 June were in line with forecasts, including revenue grew 3.4% to $2.8 billion, or 4.3% on an underlying basis versus consensus forecasts of 4.2%.

More Smith & Nephew PLC Sponsored ADR News

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Deepak Nath
Employees	19,551
Founded	1856
Website	www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now